乳腺导管原位癌：2019 年更新版。
Ductal carcinoma in situ of breast: update 2019.
机构信息
Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, United States.
Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, United States.
出版信息
Pathology. 2019 Oct;51(6):563-569. doi: 10.1016/j.pathol.2019.07.005. Epub 2019 Aug 28.
Abstract
Ductal carcinoma in situ is a non-invasive form of breast cancer. Its incidence is increasing due to widespread use of mammographic screening. It presents several diagnostic and management challenges in part due to its relatively indolent behaviour. Most series analysing biomarkers in these lesions are small (<100 patients) and large clinical trials have not been frequent. Herein, we review the recent progress made in understanding the biology of this entity and the tools available for prognostication.
摘要
导管原位癌是一种非浸润性乳腺癌。由于广泛使用乳腺 X 线筛查，其发病率正在上升。由于其相对惰性的行为，它在诊断和管理方面带来了一些挑战。大多数分析这些病变中生物标志物的系列研究规模较小（<100 例患者），大型临床试验并不频繁。本文综述了目前对该实体生物学的理解以及可用于预后评估的工具方面取得的最新进展。
相似文献
1
Ductal carcinoma in situ of breast: update 2019.乳腺导管原位癌：2019 年更新版。
Pathology. 2019 Oct;51(6):563-569. doi: 10.1016/j.pathol.2019.07.005. Epub 2019 Aug 28.
2
Pathology of ductal carcinoma in situ of the breast: a heterogeneous entity in need of greater understanding.乳腺导管原位癌的病理学：一个需要深入了解的异质性实体。
Ann Acad Med Singap. 2001 Nov;30(6):671-6; quiz 677.
3
Predictive values of BI-RADS(®) magnetic resonance imaging (MRI) in the detection of breast ductal carcinoma in situ (DCIS).乳腺影像报告和数据系统（BI-RADS®）磁共振成像（MRI）在乳腺导管原位癌（DCIS）检测中的预测价值。
Eur J Radiol. 2016 Oct;85(10):1701-1707. doi: 10.1016/j.ejrad.2016.07.010. Epub 2016 Jul 19.
4
Can dedicated breast PET help to reduce overdiagnosis and overtreatment by differentiating between indolent and potentially aggressive ductal carcinoma in situ?专门的乳腺 PET 是否有助于通过区分惰性和潜在侵袭性导管原位癌来减少过度诊断和过度治疗？
Eur Radiol. 2020 Jan;30(1):514-522. doi: 10.1007/s00330-019-06356-9. Epub 2019 Aug 2.
5
Measurements using mammography and ultrasonography underestimate the size of high-volume ductal carcinoma in situ.使用乳腺 X 线摄影术和超声检查会低估大体积导管原位癌的大小。
Am J Surg. 2021 Jun;221(6):1167-1171. doi: 10.1016/j.amjsurg.2021.03.043. Epub 2021 Mar 24.
6
[In situ ductal carcinoma of the breast: a diagnostic challenge].[乳腺原位导管癌：一项诊断挑战]
Wien Med Wochenschr Suppl. 2002(113):69-73.
7
[Ductal carcinoma in situ].导管原位癌
Ugeskr Laeger. 2018 Sep 17;180(38).
8
New insights into mammographic correlations in breast pathology.乳腺病理学中乳腺X线摄影相关性的新见解。
Curr Opin Radiol. 1991 Aug;3(4):593-601.
9
Retrospective and comparative analysis of (99m)Tc-Sestamibi breast specific gamma imaging versus mammography, ultrasound, and magnetic resonance imaging for the detection of breast cancer in Chinese women.（99m）锝-司他米比乳腺特异性γ成像与乳腺X线摄影、超声及磁共振成像在中国女性乳腺癌检测中的回顾性对比分析
BMC Cancer. 2016 Jul 11;16:450. doi: 10.1186/s12885-016-2537-1.
10
Ductal carcinoma in situ: surgery and radiotherapy.导管原位癌：手术与放疗
Breast. 2003 Dec;12(6):447-50. doi: 10.1016/s0960-9776(03)00151-6.
引用本文的文献
1
Epigenetic regulation of breast ductal carcinoma in situ by miR-217 through DNMT1 and Hedgehog-GLI pathway.miR-217通过DNMT1和Hedgehog-GLI途径对乳腺导管原位癌的表观遗传调控
J Cell Commun Signal. 2025 Sep 3;19(3):e70030. doi: 10.1002/ccs3.70030. eCollection 2025 Sep.
2
Prediction of upstaging in DCIS: the dominant role of pathological over imaging risk factors.导管原位癌（DCIS）分期升级的预测：病理因素相较于影像学风险因素的主导作用
Breast Cancer Res Treat. 2025 Oct;213(3):325-334. doi: 10.1007/s10549-025-07768-6. Epub 2025 Aug 1.
3
Can Mammography and Magnetic Resonance Imaging Predict the Preoperative Size and Nuclear Grade of Pure Ductal Carcinoma In Situ?乳房X线摄影和磁共振成像能否预测纯导管原位癌的术前大小和核分级？
Diagnostics (Basel). 2025 Jul 17;15(14):1801. doi: 10.3390/diagnostics15141801.
4
The DCIS-IBC guide board on predicting postoperative upgrading in breast ductal carcinoma in situ: clinical insights from a multicenter study.乳腺导管原位癌术后升级预测的DCIS-IBC指南委员会：一项多中心研究的临床见解
Breast Cancer Res Treat. 2025 Jun 30. doi: 10.1007/s10549-025-07763-x.
5
Nanostructured Formulations for a Local Treatment of Cancer: A Mini Review About Challenges and Possibilities.用于癌症局部治疗的纳米结构制剂：关于挑战与可能性的综述
Pharmaceutics. 2025 Feb 6;17(2):205. doi: 10.3390/pharmaceutics17020205.
6
Intratumoral Injection of mRNA-2752 and Pembrolizumab for High-Risk Ductal Carcinoma In Situ: A Phase 1 Nonrandomized Clinical Trial.瘤内注射mRNA-2752和帕博利珠单抗治疗高危导管原位癌：一项1期非随机临床试验
JAMA Oncol. 2025 Mar 1;11(3):288-292. doi: 10.1001/jamaoncol.2024.5927.
7
Changes to the US Preventive Services Task Force Screening Guidelines and Incidence of Breast Cancer.美国预防服务工作组筛查指南的变化与乳腺癌发病率
JAMA Netw Open. 2024 Dec 2;7(12):e2452688. doi: 10.1001/jamanetworkopen.2024.52688.
8
Evaluation of tumor infiltrating lymphocytes as a prognostic biomarker in patients with ductal carcinoma in situ of the breast.评估肿瘤浸润淋巴细胞作为乳腺导管原位癌患者的预后生物标志物。
Breast Cancer Res Treat. 2024 Nov;208(1):9-18. doi: 10.1007/s10549-024-07466-9. Epub 2024 Aug 24.
9
Comparison of locoregional recurrence risk among nipple-sparing mastectomy, skin-sparing mastectomy, and simple mastectomy in patients with ductal carcinoma in situ: a single-center study.保乳手术、乳腺切除术和单纯乳房切除术治疗导管原位癌患者的局部区域复发风险比较：一项单中心研究。
Breast Cancer. 2024 Nov;31(6):1010-1017. doi: 10.1007/s12282-024-01613-2. Epub 2024 Jul 17.
10
Upper Extremity Deep Vein Thrombosis in the Setting of Ductal Carcinoma In Situ: A Case Report.导管原位癌背景下的上肢深静脉血栓形成：一例报告
Cureus. 2024 Jun 6;16(6):e61805. doi: 10.7759/cureus.61805. eCollection 2024 Jun.
本文引用的文献
1
Variability in diagnostic threshold for comedo necrosis among breast pathologists: implications for patient eligibility for active surveillance trials of ductal carcinoma in situ.乳腺病理学家中对粉刺样坏死诊断阈值的变异性：对导管原位癌主动监测试验中患者入选资格的影响。
Mod Pathol. 2019 Sep;32(9):1257-1262. doi: 10.1038/s41379-019-0262-4. Epub 2019 Apr 12.
2
Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers.肿瘤浸润淋巴细胞与预后：早期三阴性乳腺癌患者的汇总分析。
J Clin Oncol. 2019 Mar 1;37(7):559-569. doi: 10.1200/JCO.18.01010. Epub 2019 Jan 16.
3
Morphologic and Molecular Features of Breast Ductal Carcinoma in Situ.乳腺导管原位癌的形态学和分子特征。
Am J Pathol. 2019 May;189(5):946-955. doi: 10.1016/j.ajpath.2018.07.031. Epub 2018 Oct 29.
4
The Emerging Roles of Steroid Hormone Receptors in Ductal Carcinoma in Situ (DCIS) of the Breast.甾体激素受体在乳腺导管原位癌（DCIS）中的新兴作用。
J Mammary Gland Biol Neoplasia. 2018 Dec;23(4):237-248. doi: 10.1007/s10911-018-9416-0. Epub 2018 Oct 18.
5
Beyond DNA: the Role of Epigenetics in the Premalignant Progression of Breast Cancer.超越DNA：表观遗传学在乳腺癌癌前进展中的作用
J Mammary Gland Biol Neoplasia. 2018 Dec;23(4):223-235. doi: 10.1007/s10911-018-9414-2. Epub 2018 Oct 10.
6
Progression-specific genes identified in microdissected formalin-fixed and paraffin-embedded tissue containing matched ductal carcinoma in situ and invasive ductal breast cancers.在包含匹配的导管原位癌和浸润性导管乳腺癌的福尔马林固定和石蜡包埋组织中鉴定出的具有特定进展阶段的基因。
BMC Med Genomics. 2018 Sep 20;11(1):80. doi: 10.1186/s12920-018-0403-5.
7
Intratumoral Heterogeneity in Ductal Carcinoma In Situ: Chaos and Consequence.导管原位癌中的肿瘤内异质性：混乱与后果
J Mammary Gland Biol Neoplasia. 2018 Dec;23(4):191-205. doi: 10.1007/s10911-018-9410-6. Epub 2018 Sep 7.
8
Breaking through to the Other Side: Microenvironment Contributions to DCIS Initiation and Progression.突破到另一侧：微环境对导管原位癌起始和进展的作用
J Mammary Gland Biol Neoplasia. 2018 Dec;23(4):207-221. doi: 10.1007/s10911-018-9409-z. Epub 2018 Aug 31.
9
A Biological Signature for Breast Ductal Carcinoma to Predict Radiotherapy Benefit and Assess Recurrence Risk.预测放疗获益和评估复发风险的乳腺导管癌生物学特征。
Clin Cancer Res. 2018 Dec 1;24(23):5895-5901. doi: 10.1158/1078-0432.CCR-18-0842. Epub 2018 Jul 27.
10
Multigene Expression Assay and Benefit of Radiotherapy After Breast Conservation in Ductal Carcinoma in Situ.多基因表达分析与保乳术后放射治疗对导管原位癌的获益。
J Natl Cancer Inst. 2017 Apr 1;109(4). doi: 10.1093/jnci/djw256.
Zotero 插件